Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Cyclacel Pharmaceuticals assumed with an Outperform at Oppenheimer » 09:01
07/18/22
07/18
09:01
07/18/22
09:01
CYCC

Cyclacel Pharmaceuticals

$1.20 /

+0.01 (+0.84%)

Oppenheimer analyst jeff…

Oppenheimer analyst jeff Jones assumed coverage of Cyclacel Pharmaceuticals with an Outperform rating and $17 price target due to a reallocation of the firm's analyst resources.

ShowHide Related Items >><<
CYCC Cyclacel Pharmaceuticals
$1.20 /

+0.01 (+0.84%)

CYCC Cyclacel Pharmaceuticals
$1.20 /

+0.01 (+0.84%)

11/18/21 Ladenburg
Cyclacel Pharmaceuticals price target lowered to $17 from $18 at Ladenburg
CYCC Cyclacel Pharmaceuticals
$1.20 /

+0.01 (+0.84%)

CYCC Cyclacel Pharmaceuticals
$1.20 /

+0.01 (+0.84%)

Over a quarter ago
Hot Stocks
Cyclacel Pharmaceuticals achieves key business objectives in 1H22 » 09:17
06/30/22
06/30
09:17
06/30/22
09:17
CYCC

Cyclacel Pharmaceuticals

$1.46 /

-0.005 (-0.34%)

Cyclacel Pharmaceuticals…

Cyclacel Pharmaceuticals announced that it has achieved key business objectives in the first half of 2022 and provided a review of progress with its two clinical stage drug candidates. Fadraciclib: Fifteen patients with advanced solid tumors and lymphomas treated with oral fadraciclib at all five dose levels as per protocol in the 065-101 dose escalation study. Demonstrated evidence of target engagement for CDK2 and CDK9 in cell assay system and patient PK data suggested that these targets are potentially inhibited at 100mg twice daily levels. A cutaneous T cell lymphoma patient achieved partial response in the first oral treatment cycle. A peripheral T cell lymphoma patient achieved 38% reduction in target lesions by PET scan in the first oral treatment cycle. An endometrial cancer patient achieved stable disease with 15% reduction of target lesions after the first oral treatment cycle. In an earlier study of intravenous fadraciclib as monotherapy, a patient with MCL1 amplified endometrial cancer achieved confirmed complete response and remains on study after two and a half years of treatment. A pancreatic cancer patient achieved stable disease by confirmatory scan for five oral treatment cycles. As no dose limiting toxicities have been observed, the Company has submitted a protocol amendment to the U.S. Food and Drug Administration to escalate to two additional dose levels before determining recommended Phase 2 dose. Based on good tolerability in 065-101, a protocol amendment in the 065-102 study of oral fadraciclib in patients with leukemia or myelodysplastic syndromes has enabled acceleration of the study by omitting dose levels two and three and now enrolling at dose level 4. CYC140: No dose limiting toxicities observed to date in 140-101, a Phase 1/2 study of oral CYC140 in solid tumors. An ovarian cancer patient in 140-101 achieved stable disease with tumor shrinkage after the first cycle. Corporate Updates: The Company is planning an R&D Day in the fall of 2022 to present updated data from the 065-101 and 140-101 clinical trials. The Company has also submitted an abstract to potentially present fadraciclib data from 065-101 at a cancer conference in the fall of 2022.

ShowHide Related Items >><<
CYCC Cyclacel Pharmaceuticals
$1.46 /

-0.005 (-0.34%)

CYCC Cyclacel Pharmaceuticals
$1.46 /

-0.005 (-0.34%)

11/18/21 Ladenburg
Cyclacel Pharmaceuticals price target lowered to $17 from $18 at Ladenburg
CYCC Cyclacel Pharmaceuticals
$1.46 /

-0.005 (-0.34%)

CYCC Cyclacel Pharmaceuticals
$1.46 /

-0.005 (-0.34%)

Hot Stocks
Cyclacel Pharmaceuticals announces Ferguson elected to board of directors » 07:13
06/22/22
06/22
07:13
06/22/22
07:13
CYCC

Cyclacel Pharmaceuticals

$1.38 /

+0.055 (+4.17%)

Cyclacel Pharmaceuticals…

Cyclacel Pharmaceuticals announced the election of Kenneth Ferguson, Ph.D., to its Board of Directors. Dr. Ferguson was elected by and will represent the 6% Convertible Exchangeable Preferred stockholders. Dr. Ferguson's professional experience includes over 30 years of scientific and drug development experience in the biopharmaceutical industry. Currently, he serves as an Operating Partner at Accelerator Life Science Partners.

ShowHide Related Items >><<
CYCC Cyclacel Pharmaceuticals
$1.38 /

+0.055 (+4.17%)

CYCC Cyclacel Pharmaceuticals
$1.38 /

+0.055 (+4.17%)

11/18/21 Ladenburg
Cyclacel Pharmaceuticals price target lowered to $17 from $18 at Ladenburg
CYCC Cyclacel Pharmaceuticals
$1.38 /

+0.055 (+4.17%)

CYCC Cyclacel Pharmaceuticals
$1.38 /

+0.055 (+4.17%)

Hot Stocks
Cyclacel Pharmaceuticals expects cash to fund operations through 2023 » 16:15
05/11/22
05/11
16:15
05/11/22
16:15
CYCC

Cyclacel Pharmaceuticals

$1.33 /

-0.165 (-11.07%)

As of March 31, 2022,…

As of March 31, 2022, cash and cash equivalents totaled $29.6 million, compared to $36.6 million as of December 31, 2021. Subsequent to the end of the first quarter, the Company received $3.6 million of United Kingdom research & development tax credits and $1.3 million in royalty receipts providing pro forma March 31, 2022, cash and cash equivalents of $34.5 million. The Company estimates that its available cash will fund currently planned programs through June 2023.

ShowHide Related Items >><<
CYCC Cyclacel Pharmaceuticals
$1.33 /

-0.165 (-11.07%)

CYCC Cyclacel Pharmaceuticals
$1.33 /

-0.165 (-11.07%)

11/18/21 Ladenburg
Cyclacel Pharmaceuticals price target lowered to $17 from $18 at Ladenburg
CYCC Cyclacel Pharmaceuticals
$1.33 /

-0.165 (-11.07%)

CYCC Cyclacel Pharmaceuticals
$1.33 /

-0.165 (-11.07%)

Earnings
Cyclacel Pharmaceuticals reports Q1 EPS (42c), consensus (68c) » 16:15
05/11/22
05/11
16:15
05/11/22
16:15
CYCC

Cyclacel Pharmaceuticals

$1.33 /

-0.165 (-11.07%)

"We are pleased to…

"We are pleased to report another productive quarter for Cyclacel, which included continued expansion of our three, registration-directed, clinical trials and publication of research findings supporting our drug development strategy," said Spiro Rombotis, Chief Executive Officer of Cyclacel. "Oral fadraciclib, our CDK2/9 drug candidate, is proving to be well tolerated in 065-101, our Phase 1/2 solid tumor and lymphoma study, having reached dose level 5 in the dose escalation stage which provides for daily dosing over 4 out of 4 weeks. In our PLK1 program, we have dosed the first patients in the streamlined Phase 1/2 trial of CYC140 for the treatment of solid tumors and lymphomas. We have optimized the properties of CYC140 to fit its apoptosis-driven mechanism, including short half-life and differentiated structural and biological properties, compared to other PLK1 inhibitors in development. We therefore believe CYC140 has the potential to demonstrate activity across a wide range of solid tumors, as a single agent and in combinations."

ShowHide Related Items >><<
CYCC Cyclacel Pharmaceuticals
$1.33 /

-0.165 (-11.07%)

CYCC Cyclacel Pharmaceuticals
$1.33 /

-0.165 (-11.07%)

11/18/21 Ladenburg
Cyclacel Pharmaceuticals price target lowered to $17 from $18 at Ladenburg
CYCC Cyclacel Pharmaceuticals
$1.33 /

-0.165 (-11.07%)

CYCC Cyclacel Pharmaceuticals
$1.33 /

-0.165 (-11.07%)

Hot Stocks
Cyclacel doses first patient in Phase 1/2 study of oral CYC140 » 09:18
04/19/22
04/19
09:18
04/19/22
09:18
CYCC

Cyclacel Pharmaceuticals

$2.00 /

-0.05 (-2.44%)

Cyclacel Pharmaceuticals…

Cyclacel Pharmaceuticals announced dosing of the first patient in the Company's streamlined, multi-cohort Phase 1/2 study of oral CYC140 in patients with advanced solid tumors and lymphomas. "With the start of this trial, Cyclacel is now enrolling patients across three registration-directed studies to evaluate safety and efficacy of our two lead drug candidates, fadraciclib and CYC140, for the treatment of various solid tumors, lymphomas and leukemias," said Spiro Rombotis, Cyclacel's President and Chief Executive Officer. "As with the fadraciclib studies, the Phase 1 stage of this trial will determine an optimal dosing regimen of oral CYC140 and provide insights with respect to safety, tolerability and clinical activity. The Phase 2 stage will enroll up to seven cohorts by histology and also a basket cohort. We expect initial data from this trial during the first half of 2023. We also look forward to reporting initial data from the fadraciclib clinical study in advanced solid tumors during the first half of 2022." The Phase 1/2 registration-directed trial, designated CYC140-101, uses a streamlined design and will first determine in a dose escalation stage the recommended Phase 2 dose for single-agent CYC140.

ShowHide Related Items >><<
CYCC Cyclacel Pharmaceuticals
$2.00 /

-0.05 (-2.44%)

CYCC Cyclacel Pharmaceuticals
$2.00 /

-0.05 (-2.44%)

11/18/21 Ladenburg
Cyclacel Pharmaceuticals price target lowered to $17 from $18 at Ladenburg
04/30/21
Fly Intel: Top five analyst initiations
04/30/21 Oppenheimer
Cyclacel Pharmaceuticals initiated with an Outperform at Oppenheimer
04/29/21 Oppenheimer
Cyclacel Pharmaceuticals initiated with an Outperform at Oppenheimer
CYCC Cyclacel Pharmaceuticals
$2.00 /

-0.05 (-2.44%)

CYCC Cyclacel Pharmaceuticals
$2.00 /

-0.05 (-2.44%)

On The Fly
Fly Intel: Pre-market Movers » 08:56
04/12/22
04/12
08:56
04/12/22
08:56
AGLE

Aeglea BioTherapeutics

$2.44 /

-0.18 (-6.87%)

, BDSX

Biodesix

$1.60 /

-0.08 (-4.76%)

, CYCC

Cyclacel Pharmaceuticals

$2.73 /

-0.11 (-3.87%)

, BCDA

BioCardia

$2.03 /

-0.06 (-2.87%)

, OGI

Organigram

$1.49 /

+0.015 (+1.02%)

, ACI

Albertsons

$34.78 /

-0.495 (-1.40%)

, KMX

CarMax

$103.20 /

+0.96 (+0.94%)

, MIMO

Airspan Networks

$2.60 /

+0.14 (+5.69%)

, MYOV

Myovant Sciences

$13.85 /

-0.6 (-4.15%)

, HPE

HP Enterprise

$15.82 /

-0.28 (-1.74%)

, CSCO

Cisco

$52.90 /

-1.4 (-2.58%)

, PFE

Pfizer

$53.97 /

-1.265 (-2.29%)

Check out this morning's…

ShowHide Related Items >><<
PFE Pfizer
$53.97 /

-1.265 (-2.29%)

OGI Organigram
$1.49 /

+0.015 (+1.02%)

MYOV Myovant Sciences
$13.85 /

-0.6 (-4.15%)

MIMO Airspan Networks
$2.60 /

+0.14 (+5.69%)

KMX CarMax
$103.20 /

+0.96 (+0.94%)

HPE HP Enterprise
$15.82 /

-0.28 (-1.74%)

CYCC Cyclacel Pharmaceuticals
$2.73 /

-0.11 (-3.87%)

CSCO Cisco
$52.90 /

-1.4 (-2.58%)

BDSX Biodesix
$1.60 /

-0.08 (-4.76%)

BCDA BioCardia
$2.03 /

-0.06 (-2.87%)

AGLE Aeglea BioTherapeutics
$2.44 /

-0.18 (-6.87%)

ACI Albertsons
$34.78 /

-0.495 (-1.40%)

AGLE Aeglea BioTherapeutics
$2.44 /

-0.18 (-6.87%)

03/08/22 H.C. Wainwright
Aeglea BioTherapeutics price target raised to $20 from $15 at H.C. Wainwright
12/06/21 Piper Sandler
Aeglea BioTherapeutics price target lowered to $9 from $12 at Piper Sandler
BDSX Biodesix
$1.60 /

-0.08 (-4.76%)

03/15/22 Canaccord
Biodesix price target lowered to $10 from $18 at Canaccord
02/15/22 Canaccord
Biodesix price target lowered to $18 from $22 at Canaccord
11/17/21 Morgan Stanley
Biodesix downgraded to Equal Weight from Overweight at Morgan Stanley
11/16/21 Canaccord
Biodesix price target lowered to $22 from $24 at Canaccord
CYCC Cyclacel Pharmaceuticals
$2.73 /

-0.11 (-3.87%)

11/18/21 Ladenburg
Cyclacel Pharmaceuticals price target lowered to $17 from $18 at Ladenburg
04/30/21
Fly Intel: Top five analyst initiations
04/30/21 Oppenheimer
Cyclacel Pharmaceuticals initiated with an Outperform at Oppenheimer
04/29/21 Oppenheimer
Cyclacel Pharmaceuticals initiated with an Outperform at Oppenheimer
BCDA BioCardia
$2.03 /

-0.06 (-2.87%)

12/20/21 H.C. Wainwright
BioCardia initiated with a Buy at H.C. Wainwright
04/16/21
Dawson James downgrades BioCardia, sees capital raise this year
04/16/21
BioCardia downgraded to Neutral from Buy at Dawson James
OGI Organigram
$1.49 /

+0.015 (+1.02%)

01/13/22 Stifel
Organigram price target lowered to C$2.25 from C$2.75 at Stifel
01/12/22 Canaccord
Organigram upgraded to Speculative Buy from Hold at Canaccord
01/06/22 Alliance Global Partners
Organigram price target lowered to C$2.25 from C$4.00 at Alliance Global Partners
11/24/21 Canaccord
Organigram price target lowered to C$3 from C$3.50 at Canaccord
ACI Albertsons
$34.78 /

-0.495 (-1.40%)

04/11/22 UBS
Albertsons price target raised to $37 from $31 at UBS
04/08/22 Cleveland Research
Albertsons continuing to outperform other grocers, says Cleveland Research
04/07/22 Deutsche Bank
Albertsons price target raised to $42 from $40 at Deutsche Bank
01/27/22 RBC Capital
Albertsons in early innings of multiple initiatives, says RBC Capital
KMX CarMax
$103.20 /

+0.96 (+0.94%)

04/08/22 Oppenheimer
CarMax price target lowered to $125 from $158 at Oppenheimer
04/06/22 BofA
CarMax downgraded to Neutral from Buy at BofA
04/06/22 BofA
CarMax downgraded to Neutral from Buy at BofA
04/04/22 Baird
CarMax price target lowered to $140 from $170 at Baird
MIMO Airspan Networks
$2.60 /

+0.14 (+5.69%)

03/25/22 Jefferies
Airspan Networks downgraded to Hold from Buy at Jefferies
03/09/22 Barrington
Airspan Networks price target lowered to $9 from $11 at Barrington
12/07/21 Jefferies
Jefferies sees Calix, Ciena among top plays on best Telco backdrop in 20 years
11/11/21 Barrington
Airspan Networks price target lowered to $11 from $15 at Barrington
MYOV Myovant Sciences
$13.85 /

-0.6 (-4.15%)

09/09/21 SVB Securities
SVB Leerink starts Myovant at Market Perform
09/09/21 SVB Securities
Myovant Sciences initiated with a Market Perform at SVB Leerink
08/19/21 Goldman Sachs
Myovant Sciences assumed with a Neutral at Goldman Sachs
05/13/21 Citi
Myovant Sciences price target lowered to $24 from $30 at Citi
HPE HP Enterprise
$15.82 /

-0.28 (-1.74%)

04/12/22 Morgan Stanley
Morgan Stanley cuts Telecom & Networking Equipment industry view to Cautious
04/12/22 Morgan Stanley
Morgan Stanley downgrades HP Enterprise ahead of expected underperformance
04/12/22 Morgan Stanley
HP Enterprise downgraded to Underweight from Equal Weight at Morgan Stanley
03/02/22 Citi
HP Enterprise price target raised to $14 from $13 at Citi
CSCO Cisco
$52.90 /

-1.4 (-2.58%)

04/12/22 Morgan Stanley
Cisco price target lowered to $59 from $61 at Morgan Stanley
04/12/22 Citi
Juniper upgraded to Neutral from Sell at Citi
04/12/22 Citi
Cisco downgraded to Sell from Neutral at Citi
04/07/22 Argus
Argus looking for upgrade opportunity for Celestica
PFE Pfizer
$53.97 /

-1.265 (-2.29%)

04/06/22 Morgan Stanley
Pfizer assumed with an Equal Weight at Morgan Stanley
04/05/22 Citi
Citi ups Pfizer target, opens 'positive Catalyst Watch'
03/28/22 KeyBanc
Codex DNA price target lowered to $8 from $30 at KeyBanc
02/15/22
FDA Vaccines and Related Biological Products Advisory Committee to hold meeting
PFE Pfizer
$53.97 /

-1.265 (-2.29%)

OGI Organigram
$1.49 /

+0.015 (+1.02%)

MYOV Myovant Sciences
$13.85 /

-0.6 (-4.15%)

MIMO Airspan Networks
$2.60 /

+0.14 (+5.69%)

KMX CarMax
$103.20 /

+0.96 (+0.94%)

HPE HP Enterprise
$15.82 /

-0.28 (-1.74%)

CYCC Cyclacel Pharmaceuticals
$2.73 /

-0.11 (-3.87%)

CSCO Cisco
$52.90 /

-1.4 (-2.58%)

BDSX Biodesix
$1.60 /

-0.08 (-4.76%)

AGLE Aeglea BioTherapeutics
$2.44 /

-0.18 (-6.87%)

ACI Albertsons
$34.78 /

-0.495 (-1.40%)

  • 10
    Feb
PFE Pfizer
$53.97 /

-1.265 (-2.29%)

KMX CarMax
$103.20 /

+0.96 (+0.94%)

HPE HP Enterprise
$15.82 /

-0.28 (-1.74%)

CSCO Cisco
$52.90 /

-1.4 (-2.58%)

ACI Albertsons
$34.78 /

-0.495 (-1.40%)

PFE Pfizer
$53.97 /

-1.265 (-2.29%)

OGI Organigram
$1.49 /

+0.015 (+1.02%)

KMX CarMax
$103.20 /

+0.96 (+0.94%)

HPE HP Enterprise
$15.82 /

-0.28 (-1.74%)

CYCC Cyclacel Pharmaceuticals
$2.73 /

-0.11 (-3.87%)

CSCO Cisco
$52.90 /

-1.4 (-2.58%)

BDSX Biodesix
$1.60 /

-0.08 (-4.76%)

AGLE Aeglea BioTherapeutics
$2.44 /

-0.18 (-6.87%)

ACI Albertsons
$34.78 /

-0.495 (-1.40%)

PFE Pfizer
$53.97 /

-1.265 (-2.29%)

MIMO Airspan Networks
$2.60 /

+0.14 (+5.69%)

KMX CarMax
$103.20 /

+0.96 (+0.94%)

HPE HP Enterprise
$15.82 /

-0.28 (-1.74%)

CSCO Cisco
$52.90 /

-1.4 (-2.58%)

ACI Albertsons
$34.78 /

-0.495 (-1.40%)

Hot Stocks
Cyclacel Pharmaceuticals announces publication on fadraciclib » 07:02
04/12/22
04/12
07:02
04/12/22
07:02
CYCC

Cyclacel Pharmaceuticals

$2.73 /

-0.11 (-3.87%)

Cyclacel Pharmaceuticals…

Cyclacel Pharmaceuticals announced a publication in the journal Leukemia titled "Cyclin-dependent kinase inhibitor fadraciclib depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells". Fadraciclib is Cyclacel's novel CDK2/9 inhibitor, currently in two Phase 1/2 trials, one for the treatment of advanced solid tumors and lymphomas and another for hematological malignancies, including patients with leukemia being treated in combination with venetoclax. "Results from this research provide further mechanistic evidence in support of our ongoing Phase 1/2 clinical study of oral fadraciclib in select hematological malignancies," said Mark Kirschbaum, M.D., Senior Vice President and Chief Medical Officer of Cyclacel. "The findings confirmed that fadraciclib suppresses MCL1 and synergizes with venetoclax, the only FDA-approved apoptosis enabling leukemia treatment. We have included a cohort within the proof-of-concept part of our Phase 1/2 study that will evaluate the combination of fadraciclib plus venetoclax in patients who have previously failed venetoclax-based regimens." Results from the study confirmed that fadraciclib inhibited CDK9 mediated transcription, reduced levels of the short-lived anti-apoptotic protein MCL1, and induced apoptosis in primary CLL cells. The data highlighted the importance of continuous treatment to prevent recovery of MCL1 protein levels. Fadraciclib was shown to combine synergistically with venetoclax. Furthermore, it was demonstrated that the best synergy, with fadraciclib and venetoclax given at the same time, was achieved in 17p deleted CLL cells, which were not sensitive to either agent alone. Fadraciclib also overcame protection mediated by stroma CLL cells and lymph node microenvironment. The data support the rationale for pursuing clinical development of fadraciclib, either alone or in combination with a BCL2 antagonist, for the treatment of CLL.

ShowHide Related Items >><<
CYCC Cyclacel Pharmaceuticals
$2.73 /

-0.11 (-3.87%)

CYCC Cyclacel Pharmaceuticals
$2.73 /

-0.11 (-3.87%)

11/18/21 Ladenburg
Cyclacel Pharmaceuticals price target lowered to $17 from $18 at Ladenburg
04/30/21
Fly Intel: Top five analyst initiations
04/30/21 Oppenheimer
Cyclacel Pharmaceuticals initiated with an Outperform at Oppenheimer
04/29/21 Oppenheimer
Cyclacel Pharmaceuticals initiated with an Outperform at Oppenheimer
CYCC Cyclacel Pharmaceuticals
$2.73 /

-0.11 (-3.87%)

CYCC Cyclacel Pharmaceuticals
$2.73 /

-0.11 (-3.87%)

On The Fly
Fly Intel: After-Hours Movers » 17:35
03/28/22
03/28
17:35
03/28/22
17:35
CYCC

Cyclacel Pharmaceuticals

$3.08 /

-0.095 (-2.99%)

, XOS

Xos

$3.11 /

-0.08 (-2.51%)

, ZEV

Lightning eMotors

$5.68 /

-0.145 (-2.49%)

, PLAY

Dave & Buster's

$43.15 /

-0.22 (-0.51%)

, LIDR

AEye

$4.89 /

-0.37 (-7.03%)

, NEO

NeoGenomics

$17.74 /

+0.13 (+0.74%)

, PINS

Pinterest

$26.46 /

+0.965 (+3.79%)

Check out this evening's…

ShowHide Related Items >><<
ZEV Lightning eMotors
$5.68 /

-0.145 (-2.49%)

XOS Xos
$3.11 /

-0.08 (-2.51%)

PLAY Dave & Buster's
$43.15 /

-0.22 (-0.51%)

PINS Pinterest
$26.46 /

+0.965 (+3.79%)

NEO NeoGenomics
$17.74 /

+0.13 (+0.74%)

LIDR AEye
$4.89 /

-0.37 (-7.03%)

CYCC Cyclacel Pharmaceuticals
$3.08 /

-0.095 (-2.99%)

CYCC Cyclacel Pharmaceuticals
$3.08 /

-0.095 (-2.99%)

11/18/21 Ladenburg
Cyclacel Pharmaceuticals price target lowered to $17 from $18 at Ladenburg
04/30/21
Fly Intel: Top five analyst initiations
04/30/21 Oppenheimer
Cyclacel Pharmaceuticals initiated with an Outperform at Oppenheimer
04/29/21 Oppenheimer
Cyclacel Pharmaceuticals initiated with an Outperform at Oppenheimer
XOS Xos
$3.11 /

-0.08 (-2.51%)

12/08/21 BofA
Xos initiated with an Underperform at BofA
12/02/21 Goldman Sachs
Xos initiated with a Neutral at Goldman Sachs
10/11/21 Wedbush
Xos initiated with an Outperform at Wedbush
09/28/21 Colliers
Xos assumed with a Buy at Colliers
ZEV Lightning eMotors
$5.68 /

-0.145 (-2.49%)

03/14/22 Benchmark
Lightning eMotors price target lowered to $9 from $14 at Benchmark
10/05/21 DA Davidson
DA Davidson sees 'positive takeaways' from meeting with Lightning eMotors
08/19/21 Benchmark
Lightning eMotors price target lowered to $14 from $17 at Benchmark
08/17/21 Northland
Lightning Motors sales estimates for 2021, 2022 reduced at Northland
PLAY Dave & Buster's
$43.15 /

-0.22 (-0.51%)

03/24/22 Gordon Haskett
Gordon Haskett sees Q4 miss for Dave & Buster's but says shares 'compelling'
03/01/22 Raymond James
Dave & Buster's added to Analyst Current Favorites list at Raymond James
01/14/22 Gordon Haskett
Gordon Haskett upgrades 'increasingly compelling' Dave & Buster's to Buy
01/14/22 Gordon Haskett
Dave & Buster's upgraded to Buy from Hold at Gordon Haskett
LIDR AEye
$4.89 /

-0.37 (-7.03%)

11/10/21 DA Davidson
AEye initiated with Buy, $15 target at DA Davidson
11/10/21 DA Davidson
AEye initiated with a Buy at DA Davidson
10/25/21 Roth Capital
AEye initiated with a Buy at Roth Capital
09/23/21 Guggenheim
AEye initiated with a Buy at Guggenheim
NEO NeoGenomics
$17.74 /

+0.13 (+0.74%)

02/24/22 Craig-Hallum
NeoGenomics price target lowered to $30 from $46 at Craig-Hallum
02/24/22 Raymond James
NeoGenomics price target lowered to $24 from $53 at Raymond James
01/18/22 Stephens
NeoGenomics assumed with an Overweight at Stephens
12/16/21 Cowen
NeoGenomics initiated with an Outperform at Cowen
PINS Pinterest
$26.46 /

+0.965 (+3.79%)

03/28/22 Morgan Stanley
Pinterest cut to Equal Weight at Morgan Stanley amid challenging user trends
03/28/22 Morgan Stanley
Pinterest downgraded to Equal Weight from Overweight at Morgan Stanley
03/28/22 Loop Capital
Pinterest price target lowered to $34 from $50 at Loop Capital
03/17/22 Cleveland Research
Pinterest downgraded to Neutral from Buy at Cleveland Research
ZEV Lightning eMotors
$5.68 /

-0.145 (-2.49%)

XOS Xos
$3.11 /

-0.08 (-2.51%)

PLAY Dave & Buster's
$43.15 /

-0.22 (-0.51%)

PINS Pinterest
$26.46 /

+0.965 (+3.79%)

NEO NeoGenomics
$17.74 /

+0.13 (+0.74%)

LIDR AEye
$4.89 /

-0.37 (-7.03%)

CYCC Cyclacel Pharmaceuticals
$3.08 /

-0.095 (-2.99%)

PINS Pinterest
$26.46 /

+0.965 (+3.79%)

NEO NeoGenomics
$17.74 /

+0.13 (+0.74%)

ZEV Lightning eMotors
$5.68 /

-0.145 (-2.49%)

XOS Xos
$3.11 /

-0.08 (-2.51%)

PLAY Dave & Buster's
$43.15 /

-0.22 (-0.51%)

PINS Pinterest
$26.46 /

+0.965 (+3.79%)

NEO NeoGenomics
$17.74 /

+0.13 (+0.74%)

LIDR AEye
$4.89 /

-0.37 (-7.03%)

ZEV Lightning eMotors
$5.68 /

-0.145 (-2.49%)

XOS Xos
$3.11 /

-0.08 (-2.51%)

PLAY Dave & Buster's
$43.15 /

-0.22 (-0.51%)

PINS Pinterest
$26.46 /

+0.965 (+3.79%)

LIDR AEye
$4.89 /

-0.37 (-7.03%)

Earnings
Cyclacel Pharmaceuticals reports Q4 EPS (54c), consensus (65c) » 16:12
03/28/22
03/28
16:12
03/28/22
16:12
CYCC

Cyclacel Pharmaceuticals

$3.15 /

-0.025 (-0.79%)

As of December 31, 2021,…

As of December 31, 2021, cash and cash equivalents totaled $36.6M, compared to $33.4M as of December 31, 2020. "2021 was a year of solid execution, as the clinical and corporate objectives achieved by the Cyclacel team have positioned us to reach important milestones in 2022. These include initial data from the dose escalation stage of the ongoing Phase 1/2 study of fadraciclib, our CDK2/9 inhibitor, in advanced solid tumors," said Spiro Rombotis, president and CEO. "Enrollment has gone well with three new patients treated at dose level 4 at our two U.S. sites and two internationally recognized, cancer centers in Asia and Western Europe who recently joined the study. In 2022 we plan to report new clinical and preclinical evidence supporting the unique properties and therapeutic potential of fadraciclib. We believe that fadraciclib is emerging as the only transcriptional CDK inhibitor in development to have demonstrated single-agent activity and tolerable daily dosing by mouth in patients with solid tumors. If confirmed with additional data, fadraciclib may emerge as an important alternative for the treatment of advanced solid tumors in patients failing available therapies."

ShowHide Related Items >><<
CYCC Cyclacel Pharmaceuticals
$3.15 /

-0.025 (-0.79%)

CYCC Cyclacel Pharmaceuticals
$3.15 /

-0.025 (-0.79%)

11/18/21 Ladenburg
Cyclacel Pharmaceuticals price target lowered to $17 from $18 at Ladenburg
04/30/21
Fly Intel: Top five analyst initiations
04/30/21 Oppenheimer
Cyclacel Pharmaceuticals initiated with an Outperform at Oppenheimer
04/29/21 Oppenheimer
Cyclacel Pharmaceuticals initiated with an Outperform at Oppenheimer

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.